Search Results
Dr. McCloskey Discusses IDH Inhibitors in AML
IDH1/2 inhibitors for AML
Dr. McCloskey on the Results of the ASCERTAIN Trial in MDS
The promising role of IDH inhibitors in AML
IDH inhibitors
Dr. McCloskey Discusses Targeting CD19 in B-Cell ALL
James McCloskey, MD, considers how the role of molecular profiling in AML is changing
James McCloskey, MD, elaborates on the role of molecular testing in newly diagnosed AML
James McCloskey, MD, speculates on the landscape of MDS as a result of data presented at ASH '19
Dr. Mannis Talks About Emerging Treatments for Acute Myeloid Leukemia
Venetoclax-IDH inhibitor combination therapy for AML
What are the latest updates on the IDH1 and IDH2 inhibitor studies?
